



## Uganda Virus Research Institute

Plot 51-59, Nakiwogo Road, Entebbe  
P.O. Box 49, Entebbe-Uganda  
Tel: +256 414 320 385 / 6  
Fax: +256 414 320 483  
Email: directoruvri@uvri.go.ug



Dr Henning Gädeke, Chair of the Global Health EDCTP3 Joint Undertaking Governing Board  
c/o Dr Michael Makanga, Executive Director Global Health EDCTP3 Joint Undertaking Executive  
Director  
Global Health EDCTP3 Joint Undertaking  
56 – 60 Avenue de la Toison d’Or  
1060 Brussels  
Belgium

28th April 2026

### Letter of endorsement

Dear Sir/Madam,

On behalf of Uganda National Health Research Organisation (**UNHRO**), a public entity registered in Plot 2, Berkeley Lane, P.O. Box 465, Entebbe, Uganda, and in accordance with Council Regulation (EU) No 2085/2021 of 19<sup>th</sup> November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU) under the call topic *Evaluating a Multi-Valent Aerosol Booster TB Vaccine for Adolescents and Young Adults in Diverse African Settings: T5 TBVAC*.

The Uganda National Health Research Organisation is the national body mandated to coordinate, regulate, and promote health research in Uganda, with a strong focus on generating evidence-based solutions to priority public health challenges. Its objectives are closely aligned with those of the Global Health EDCTP3 Joint Undertaking, particularly in strengthening clinical research capacity, supporting high-quality collaborative trials, and accelerating the development of effective interventions against infectious diseases such as tuberculosis. This alignment underpins UNHRO’s role as Scientific Lead in this application and its commitment to supporting the consortium through its research institute, the Uganda Virus Research Institute, and its on-campus partner, the MRC/UVRI and LSHTM Uganda Research Unit, to deliver impactful, high-quality research outcomes.

The in-kind contribution will be provided over the full duration of the T5 TBVAC project and is directly aligned with the implementation of key project activities across multiple work packages. It is particularly relevant to the successful delivery of WP3 (Clinical and Immunological Evaluation of ChAdOx1 T5) and WP5 (Data and Output Management, Dissemination, Exploitation and Communication), while also supporting activities under WP3, WP4 and WP6. These contributions will strengthen the project’s capacity to conduct high-quality clinical research, ensure effective community engagement, support robust data generation and management, and facilitate timely dissemination and translation of findings. Overall, the support provided is critical to achieving the scientific, operational and impact objectives of the T5 TBVAC project.

The in-kind contribution provided by UNHRO, through its partner MUL, will include provision of salary for Professor Elliott, head of the MUL Vaccine Research Theme and Scientific Lead for this project; provision of relevant research support platforms including well-resourced immunology and sequencing platforms, ISO-accredited clinical diagnostic laboratories, a clinical research facility suitable for the

experimental medicine and early phase studies in this project, statistical and data management systems, research support, project management and reporting, communications, engagement, knowledge transfer and training platforms. We estimate the total value of this contribution to be 1,031,250 EUR.

**We confirm the following:**

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes, and particularly the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.
6. If our letter is accepted, and without prejudice to point 2, we authorise Global Health EDCTP3 JU to communicate about our contribution and to display our logo in its public communication materials for the purpose of acknowledging our role as a contributing partner.
7. If we are ineligible as a contributing partner but our contribution can be considered through the EDCTP Association, we authorise Global Health EDCTP3 JU to share this letter and our contact details with the EDCTP Association as proof of our declared co-investment.

Yours sincerely,



**Dr Samuel Okware**

**Director General**

**Uganda National Health Research Organisation**